<DOC>
	<DOCNO>NCT02787109</DOCNO>
	<brief_summary>The present trial phase I first human , double blind , parallel placebo control trial SSI 's adjuvanted chlamydia vaccine CTH522 : CTH522-CAF01 ( CAF01 adjuvant system ) CTH522-Al ( OH ) 3 . The trial conduct Imperial College Research site United Kingdom . Subjects randomly assign one follow three treatment group ratio 3:3:1 . This trial consist 10 visit 5 telephonic interview</brief_summary>
	<brief_title>Safety Chlamydia Vaccine CTH522 Healthy Women Aged 18 45 Years</brief_title>
	<detailed_description />
	<mesh_term>Chlamydia Infections</mesh_term>
	<mesh_term>Aluminum Hydroxide</mesh_term>
	<criteria>1 . Is healthy female 18 45 year age day first trial vaccination 2 . Has provide sign informed consent 3 . Is willing likely comply trial procedure 4 . Is prepared grant authorise person access medical record 5 . Willing use acceptable contraceptive measures* trial ( 2 week 2 week trial ) Heterosexually active female capable become pregnant must ( addition require male partner use condom ) agree use hormonal contraception , complete abstinence , least 2 week first vaccination least 2 week last . ( Note : Periodic abstinence [ e.g . calendar , ovulation , symptothermal , postovulation method ] withdrawal intrauterine device intrauterine hormone release system progestogenonly oral hormonal contraception , inhibition ovulation primary mode action , acceptable method contraception ) 1 . Has confirm history Pelvic Inflammatory Disease significant gynaecological disease 2 . Is positive C. trachomatis ( PCR ) 3 . Is positive gonorrhoea ( urine ) , HIV , Hepatitis B/C , syphilis ( blood ) 4 . Has positive pregnancy test 5 . Has significant active disease cardiac , liver , immunological , neurological , psychiatric ; clinically significant abnormality haematological biochemical parameter . 6 . Has BMI 35 kg/m2 great 7 . Is currently participate another clinical trial investigational noninvestigational drug device 8 . Has receive , plan receive , active immunisation within 14 day start trial immunisation visit trial 9 . Is currently receive treatment immunosuppressive agent e.g . oral , inhaled , nasal injected corticosteroid . ( Topical steroid allow , unless apply IM injection site . ) 10 . Is use intrauterine device 11 . Has condition opinion investigator suitable participation trial 12 . Known confirm allergy vaccine constituent</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Safety</keyword>
	<keyword>Immunogenicity</keyword>
	<keyword>Phase I</keyword>
</DOC>